Loading clinical trials...
Loading clinical trials...
The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab an...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Gilead Sciences
Collaborators
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT06870760 · Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, and more
NCT05529069 · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, and more
NCT07125872 · Relapsed B-Cell Non Hodgkin Lymphoma
NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more
University of Alabama At Birmingham (Uab)
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
Stanford Cancer Center
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions